• Paris (France), February 5, 2024 – 7:00 p.m. CET – Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.Using the authorisation granted by the Shareholders’ General Meeting of 6th February 2023, the Board of Directors held today decided to reduce the share capital by eliminating part of the losses incurred, by an amount of €16,980,070.03.This capital reduction, motivated by losses, is being carried out by reducing the nominal value of the Company’s shares from €0.25 euro to €0.14. Its purpose is to facilitate any new financial transactions that may be appropriate in the future.The Company points out that this is a purely technical operation. Neither shareholders’ equity nor the rights of holders of financial instruments will be affected.

    Following this operation, the Company’s share capital will amount to €21,610,998.20, divided into 154,364,273 ordinary shares with a par value of €0.14 each.


    About Valerio Therapeutics

    Valerio Therapeutics (Euronext Growth Paris) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners..

    platON is Valerio Therapeutics’s proprietary chemistry platform of DNA decoy therapeutics, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its DNA decoy therapeutic mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe and the US in combination with other treatment modalities in difficult-to-treat solid tumors.

    VIO-01 (formerly OX425), the second compound from platON, is a novel pan-DDR Decoy with high antitumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. OX425 is currently undergoing IND-enabling preclinical development.

    For further information, please visit www.valeriotx.com. 




    Forward looking statements

    This communication expressly or implicitly contains certain forward-looking statements concerning Valerio Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Valerio Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Valerio Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Valerio Therapeutics to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (https://valeriotx.com/) and/or the AMF (www.amf-france.org).



    Valerio Therapeutics

    Investor Relations


    +33 1 45 58 76 00